<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193595</url>
  </required_header>
  <id_info>
    <org_study_id>TCD11379</org_study_id>
    <secondary_id>2009-017797-20</secondary_id>
    <nct_id>NCT01193595</nct_id>
  </id_info>
  <brief_title>Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open-label, Non-randomized, Dose Escalation, Safety and Pharmacokinetic Phase I Study of Ombrabulin (AVE8062) in Combination With Bevacizumab Administered by Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - To determine the maximum administered dose (MAD) and the maximum tolerated dose (MTD) of&#xD;
      ombrabulin in combination with best tolerated dose of bevacizumab based on the incidence of&#xD;
      related Dose Limiting Toxicities (DLTs).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the overall safety profile of the combination&#xD;
&#xD;
        -  To characterize the pharmacokinetic (PK) profile of both ombrabulin and bevacizumab when&#xD;
           given in combination&#xD;
&#xD;
        -  To evaluate preliminary evidence of anti-tumor activity&#xD;
&#xD;
        -  To assess the pharmacodynamic effect using (Dynamic Contrast Enhanced Ultra-Sound)&#xD;
           DCE-US, measuring biomarkers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study for each patient will include an up to 28-day screening phase,&#xD;
      21-day study treatment cycles, an end of treatment visit with a follow-up period. Each&#xD;
      patient will participate in only one dose group and will receive AVE8062 with bevacizumab&#xD;
      every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or&#xD;
      Investigator's decision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs) that will define the MTD</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall safety profile of the combination</measure>
    <time_frame>up to a maximum follow-up of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of ombrabulin</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of bevacizumab</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary evidence of antitumor activity according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</measure>
    <time_frame>up to a maximum follow-up of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effect (biomarkers)</measure>
    <time_frame>cycle 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Neoplasms, Malignant</condition>
  <arm_group>
    <arm_group_label>AVE8062/ bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The combination of ombrabulin and bevacizumab will be administered every 3 weeks according to the following schedule: One day 1, ombrabulin will be administered as a 30 minutes intravenous (i.v) infusion. Bevacizumab will be administered as a 30-90 minutes i.v. infusion 24 hours after the end of ombrabulin infusion on day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombrabulin (AVE8062)</intervention_name>
    <description>Pharmaceutical form:Solution for infusion&#xD;
Route of administration: Intravenous</description>
    <arm_group_label>AVE8062/ bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Pharmaceutical form:Solution for infusion&#xD;
Route of administration: Intravenous</description>
    <arm_group_label>AVE8062/ bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven solid malignant tumor at the first diagnosis&#xD;
             with the exception of squamous non small cell lung cancer (NSCLC).&#xD;
&#xD;
          -  Advanced neoplastic disease (i.e. metastatic or locally unresectable advanced disease)&#xD;
&#xD;
          -  Presence of one measurable lesion at baseline in the MTD expanded cohort&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  ECOG (Eastern cooperativeOncology Group) performance status &gt; 1&#xD;
&#xD;
          -  Concurrent treatment with any other anticancer therapy&#xD;
&#xD;
          -  Pericardial effusion requiring intervention (drainage)&#xD;
&#xD;
          -  History of brain metastasis, spinal cord compression or carcinomatous meningitis or&#xD;
             new evidence of brain metastasis on screening Computed tomography (CT) or Magnetic&#xD;
             resonance imaging (MRI) scan&#xD;
&#xD;
          -  Diagnosis of squamous Non Squamous Cell Lung Cancer (NSCLC) or with mixed cell type&#xD;
             with predominant squamocellular histology&#xD;
&#xD;
          -  Hormone sensitive prostate cancer&#xD;
&#xD;
          -  Abdominal Radiotherapy&#xD;
&#xD;
          -  Major surgery within the last month of study enrollment or surgical wound not fully&#xD;
             healed before study enrollment&#xD;
&#xD;
          -  High cumulative doses of anthracycline&#xD;
&#xD;
          -  Inadequate organ function&#xD;
&#xD;
          -  Inadequate hematology function or poor bone marrow reserve&#xD;
&#xD;
          -  Any of the following within 6 months prior to study enrollment: peptic ulcer disease,&#xD;
             erosive oesophagitis or gastritis, infectious or inflammatory bowel disease and&#xD;
             diverticulitis&#xD;
&#xD;
          -  Any history or underlying cardiac condition that may increase the risks associated&#xD;
             with the study participation or administration of the investigational products, or&#xD;
             that may interfere with the interpretation of the results.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380002</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380001</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826001</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

